goldennet

Search

Please select the unit you wish to search and enter the keyword in the text field below.

  • PRESSROOM
  • PUBLICATIONS
  • PIPELINE
  • TECHNOLOGY
  • Leave TLC website?

    You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.{br}{br}TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.{br}{br}Click “STAY” to return to tlcbio.com or “CONTINUE” to proceed.

    STAY
    CONTINUE
    Platform for Showcasing Research Achievements
    Publications

    Stay Updated on the Latest Academic Trends and Research Progress through Our Journals

  • TLC599
  • TLC590
  • TLC178
  • TLC19
  • Others
  • OOPS!
    Page not found.

    We are sorry, the page you requested could not be found.

      • TLC599
      A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
      • Author(s)
        George Spencer-Green, David Hunter, Thomas Schnitzer, Sheue-Fang Shih, Tien-Tzu Tai, Cathy Kao and Siao-Ning Huang
      • Published
        ACR Convergence 2023
      • TLC599
      Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
      • Author(s)
        Sheue-Fang Shih, Carl Brown, Tien-Tzu Tai and Wing Chuang; Taiwan Liposome Company (TLC), Ltd., Taipei, Taiwan
      • TLC599
      Single Intra-articular injection of TLC599 in Patients with Osteoarthritis Knee Pain: Subgroup Analyses of a Placebo-controlled 24-week Phase 2 Trial
      • Author(s)
        C. Brown, C.-F. Wu, W. Chuang, S.-F. Shih. Taiwan Liposome Company, Taipei City, Taiwan
      • TLC599
      Single Intra-articular Injection of TLC599 Provided Sustained Pain Relief through 24 Weeks in Participants with Symptomatic Knee Osteoarthritis
      • Author(s)
        D. Hunter, C-C. Chang, J-C. Wei, H-Y. Lin, C. Brown, S-F. Shih; Univ. of Sydney, Sydney, Australia, Royal North Shore Hosp., Sydney, Australia, Div. of Allergy, Immunology and Rheumatology, Dept. of Internal Med., Sch. of Med., Coll. of Med., Taipei Med. Univ., Taipei, Taiwan, Div. of Allergy, Immunology and Rheumatology, Chung Shan Med. Univ. Hosp., Taipei, Taiwan, Dept. of Internal Med., Cheng Hsin Gen. Hosp., Taipei, Taiwan, Dept. of Allergy, Immunology and Rheumatology, Taipei Veterans Gen. Hosp., Taipei, Taiwan, Taiwan Liposome Company, Taipei, Taiwan
      • Published
        2019 OARSI World Congress on Osteoarthritis
      • TLC599
      Safety, Tolerability, and Efficacy of a Novel Sustained-release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) in Patients with Knee Osteoarthritis
      • Author(s)
        Chien-Chih Lai, Chao-Ching Chiang, Chyou-Shen Lee, Chi-Ching Chang, Hsiao-Yi Lin, Tien-Ling Chen, and Sheue-Fang Shih
      • Published
        20th Asia Pacific League of Associations for Rheumatology Congress
      • TLC599
      Cartilage Damage and Synovial Toxicokinetic Study of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) following Intra-articular Injection in Healthy Dogs and Rabbits
      • Author(s)
        W-N. Yu, M-J Wu, P-C Chang, S-F Shih; Taiwan Liposome Company, Taipei, Taiwan
      • Published
        2019 OARSI World Congress on Osteoarthritis